Key Takeaways
- • MBK Partners and UCK Partners completed acquisition of Osstem Implant, Korea's largest dental implant manufacturer, at an enterprise value of KRW 3.64 trillion, securing management control through a special purpose company (Dentistry Investment) with ownership reaching 80.42% by April 2023.
- • Osstem delisted from KOSDAQ in August 2023 and is executing aggressive overseas expansion strategy under private ownership, with Q1 2026 overseas revenue representing 68.1% of total consolidated revenue ($148.50 million of $218.21 million total).
- • US production facility operating at 109.1% capacity utilization in Q1 2026, significantly outpacing the Busan hub's 87.4%, signaling accelerated US manufacturing investment as part of value enhancement roadmap ahead of anticipated exit.
- • Consortium pursuing multi-vector value creation including US plant expansion, China distribution network growth, R&D investment acceleration, and subsidiary mergers to optimize the unlisted corporate structure for exit preparation.
- • Fresh scrutiny has emerged regarding the restructuring, with reported tension between MBK and founder Chairman Choi over the investment strategy and associated debt burden, raising governance questions within the consortium structure.
Summary
The MBK Partners and UCK Partners consortium acquired Osstem Implant, the world's fourth-largest dental implant manufacturer and Korea's market leader, through a tender offer structure completed in 2023. The consortium's special purpose company, Dentistry Investment, initially acquired a 64.71% stake in February 2023 to become the largest shareholder, subsequently raising ownership to 80.42% through an additional tender offer in April. The total enterprise value was KRW 3.64 trillion. The company completed voluntary delisting from KOSDAQ in August 2023, transitioning to private status to enable operational restructuring and strategic repositioning without public market constraints.
Since taking private ownership, the consortium has implemented a deliberate overseas expansion strategy designed to enhance enterprise value ahead of a planned exit. First-quarter 2026 financial results demonstrate the effectiveness of this approach: consolidated revenue reached $218.21 million (₩328.4 billion) with operating income of $18.80 million (₩28.3 billion), while full-year 2025 consolidated revenue totaled $885.58 million (₩1.3327 trillion). Overseas markets now represent 68.1% of total revenue at $148.50 million, a substantial shift in geographic revenue composition reflecting deliberate market diversification away from Korea-dependent concentration.
Production infrastructure investment has intensified, particularly in the United States. The US subsidiary's production facility operated at 109.1% capacity utilization in Q1 2026, substantially exceeding the domestic Busan hub's 87.4% utilization rate. This disparity underscores the consortium's prioritization of North American manufacturing expansion as a cornerstone of value creation, supported by concurrent investments in China distribution network development, accelerated R&D spending, and planned subsidiary mergers to optimize the unlisted operational structure.
However, the restructuring effort has attracted regulatory and stakeholder scrutiny. Tensions have reportedly emerged between MBK and founder Chairman Choi regarding investment direction, debt burden management, and governance approach during the transition to private ownership. These friction points suggest potential divergence between financial sponsor objectives and founder interests, a dynamic common in consortium-led acquisitions of founder-led companies but warranting monitoring given Osstem's strategic importance as a market leader and the scale of enterprise value involved.
Since taking private ownership, the consortium has implemented a deliberate overseas expansion strategy designed to enhance enterprise value ahead of a planned exit. First-quarter 2026 financial results demonstrate the effectiveness of this approach: consolidated revenue reached $218.21 million (₩328.4 billion) with operating income of $18.80 million (₩28.3 billion), while full-year 2025 consolidated revenue totaled $885.58 million (₩1.3327 trillion). Overseas markets now represent 68.1% of total revenue at $148.50 million, a substantial shift in geographic revenue composition reflecting deliberate market diversification away from Korea-dependent concentration.
Production infrastructure investment has intensified, particularly in the United States. The US subsidiary's production facility operated at 109.1% capacity utilization in Q1 2026, substantially exceeding the domestic Busan hub's 87.4% utilization rate. This disparity underscores the consortium's prioritization of North American manufacturing expansion as a cornerstone of value creation, supported by concurrent investments in China distribution network development, accelerated R&D spending, and planned subsidiary mergers to optimize the unlisted operational structure.
However, the restructuring effort has attracted regulatory and stakeholder scrutiny. Tensions have reportedly emerged between MBK and founder Chairman Choi regarding investment direction, debt burden management, and governance approach during the transition to private ownership. These friction points suggest potential divergence between financial sponsor objectives and founder interests, a dynamic common in consortium-led acquisitions of founder-led companies but warranting monitoring given Osstem's strategic importance as a market leader and the scale of enterprise value involved.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.